Out-licensing
- Out-licensing
- View
Cancer - Novel Gene (TADG-12) (98-24)
Mechanism of action
Full description
TADG-12 is a new member of the serine protease family. This novel Tumor Antigen Derived Gene, i.e. TADG, was identified by differential PCR display using both normal ovarian tissue and ovarian carcinoma. More specifically, TADG-12 was identified using primers to the conserved histidine (sense) and the conserved aspartic acid (antisense). Northern blot analysis utilizing cDNA probe from the 5' domain of TADG-12 revealed three transcripts of 2.6kb, 1.7kb, and 0.9kb. The presence of these transcript varients are noted to be overexpressed in several subtypes of ovarian carcinomas, and not in normal ovary.
Reference: Biochimica et Biophysica Acta 1502, (2000) 337 - 350
98-24
Development status
Patent information
US Patents #6,291,663; #6,294,663, #6,942,978; #7,265,216, #7,067,630 + National Filings
License Status: Exclusive Licensing Available in all Fields except Diagnostic
Type of business relationship sought
Additional Licensing Partner to further the commercialization of the Vaccine, Small Molecule, Antisense and Gene Therapy applications of this patented technology
Patent number
Related reports
Licensing contact
Company details
Medical School - Teaching Hospital - Research Institution
View profileRelated technologies
- Transdermal Fentanyl
- Orally Bioavailable LHRH Antagonistic Peptidomimetics: Treatment of Endometriosis, Uterus Myoma, BPH and Malignant Disorders such as Breast and Prostate Cancer
- Genexol PM
- 4 and 8 mg Ondansetron RapidFilm
- Product enhancement of small and large molecules in a range of dosage forms
Related categories
- Industry sector
- Academic/Research / Biotech
- Biotechnology / Gene therapy
- Research tools / Vectors
- Therapeutic target
- Oncology
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us